RIL
ADCT icon

Rothschild Investment LLC’s ADC Therapeutics ADCT Stock Holding History

Rothschild Investment LLC’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129 Buy
121
+120
+12,000% +$350 ﹤0.01% 3491
2026
Q1 		$4 Sell
1
-9
-90% -$35 ﹤0.01% 3596
2025
Q4 		$35 Buy
+10
New +$41 ﹤0.01% 3296

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rothschild Investment LLC's ADCT Position: Q2 2026 in Review

Rothschild Investment LLC increased its ADC Therapeutics (ADCT) stake by 12,000% in Q2 2026, buying an estimated $350 and bringing the position to 121 shares worth $129. The position accounts for ﹤0.01% of the portfolio, ranked #3491.

Rothschild Investment LLC first reported a position in ADCT in Q4 2025 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Rothschild Investment LLC held 121 shares of ADC Therapeutics worth $129 as of Q2 2026.
  • Rothschild Investment LLC bought 120 ADC Therapeutics shares in Q2 2026, an estimated $350.
  • ADC Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3491 holding.
  • Rothschild Investment LLC first reported a position in ADC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.